What is Eton Pharmaceuticals Price-to-Operating-Cash-Flow?
As of today (2024-05-12), Eton Pharmaceuticals's share price is $3.43.
Eton Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.26. Hence, Eton Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is 13.14.
The historical rank and industry rank for Eton Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:
ETON'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.89 Med: 16.86 Max: 48.41
Current: 13.14
During the past 7 years, Eton Pharmaceuticals's highest Price-to-Operating-Cash-Flow Ratio was 48.41. The lowest was 9.89. And the median was 16.86.
Eton Pharmaceuticals's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $0.02.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.26.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Eton Pharmaceuticals was 38.50% per year.
During the past 7 years, Eton Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 47.20% per year. The lowest was 47.20% per year. And the median was 47.20% per year.
Eton Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Eton Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eton Pharmaceuticals Price-to-Operating-Cash-Flow Chart
|
Eton Pharmaceuticals Annual Data
|
|
Trend |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
- |
- |
- |
14.69 |
16.47 |
|
Eton Pharmaceuticals Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
14.69 |
46.95 |
13.58 |
11.65 |
16.47 |
Competitive Comparison of Eton Pharmaceuticals's Price-to-Operating-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eton Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Eton Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Eton Pharmaceuticals Price-to-Operating-Cash-Flow Calculation
Eton Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 3.43 | / | 0.261 |
| = | 13.14 |
Eton Pharmaceuticals's Share Price of today is $3.43.
Eton Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Eton Pharmaceuticals (Eton Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eleven product candidates in various stages of development.
Executives
| David Krempa |
officer: Chief Business Officer |
29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010 |
| Sean Brynjelsen |
director, officer: President & CEO |
C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010 |
| James R. Gruber |
officer: Chief Financial Officer |
618 AMES STREET, LIBERTYVILLE IL 60048 |
| Opaleye Management Inc. |
10 percent owner |
ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
| William Wilson Troutman |
officer: CFO, Treasurer & Secretary |
21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010 |
| Imprimis Pharmaceuticals, Inc. |
10 percent owner |
102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215 |
| Jennifer Mckie Adams |
director |
5410 TENNESSEE AVE, NASHVILLE TN 37209 |
| Charles J Casamento |
director |
99 BELBROOK WAY, ATHERTON CA 94027 |
| Norbert G Riedel |
director |
BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015 |
| Mark L Baum |
director |
C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130 |
| Paul V Maier |
director |
3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
Eton Pharmaceuticals (Eton Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ETON has been successfully added to your